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ABSTRACT 
 
Proteasome inhibition has been demonstrated to be a promising strategy for cancer therapy. The chymotrypsin-
like activity of the 20S catalytic unit of the 26S proteasome is known to be critical for cancer cell survival. 
Inhibition of the proteasomal activity leads to tumor cell death. Murraya koenigii Spreng a medically important 
herb of Asian origin, is rich in phenolic content, and dietary polyphenols are known to act as proteasome 
inhibitors. This study was aimed at testing the cytotoxic and proteasomal inhibitory potential of M. koenigii leaf 
extract in four different human cell lines namely; colon, prostate, liver and cervical cancer. The cytotoxicity of 
M. koenigii leaf extract was tested by the MTT assay, inhibition of growth by colony formation assay and 
inhibition of the chymotrypsin-like (Ch-L) activity of the 26S proteasome using a specific fluorogenic substrate by 
fluorometry. There was a dose-dependent decrease in cell viability/proliferation with M. koenigii leaf extract 
treatment in all the cell lines tested. In line with the cell viability data there was a dose-dependent decrease 
in growth as observed by decreased colony formation in the cell lines tested. M. koenigii extract decreased the 
Ch-L activity of the endogenous proteasome in both intact cells and cell extracts in all the four cancer cell 
lines. Our results suggest that the proteasome is a target for M. koenigii leaf extract in various cancer cell 
lines and that inhibition of the proteasome may be one of the mechanisms responsible for its anticancer 
potential. 
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Introduction 
Cancer is a heterogeneous disease 
characterized by uncontrolled growth of cells leading 
to impairment of normal physiological functions. 
Annually 12.7 million people are diagnosed with 
cancer and approximately 7.6 million die from the 
disease.1 Tumor cells have multiple alterations in their 
signaling pathways which results in increased growth 
and proliferation.2 In recent years, tumor cells have 
been demonstrated to possess significantly higher 
proteasome activity than normal cells which is needed 
for their growth and survival.3 In tumor cells the 
proteasome functions to promote cell proliferation 
and protects against apoptosis.4  Inhibition of the 
tumor cell proteasome, specifically the chymotrypsin-
like (Ch-L) activity of the 20S proteasome is known to 
lead to apoptosis and tumor cell death.5 The 
eukaryotic proteasome is a highly conserved, large 
multi-catalytic, multi-subunit complex possessing three 
distinct  protein cleaving activities, associated with 
three different β subunits respectively: chymotrypsin-
like activity (β5 subunit), trypsin-like activity (β2 
subunit), and caspase-like activity (β1 subunit).6 It 
regulates several cellular processes such as cell-cycle 
regulation, apoptosis, signal transduction and cell 
differentiation.4 Proteasome inhibitors are now being 
used to treat solid and hematological malignancies 
either as mono-therapy or in combination therapy to 
overcome drug resistance.7 Natural proteasome 
inhibitors are now being studied due to toxicity and 
stability issues with synthetic inhibitors.8 Anticancer 
effects of natural products are supported by results.9,10 
from epidemiological, cell culture and animal studies 
Murraya koenigii (commonly called as curry leaf plant), 
is a small aromatic tree belonging to the family 
Rutaceae. It is extensively used in Indian culinary 
practices for seasoning and flavoring dishes.11 
Traditionally, this plant is used as a medicine in eastern 
Asia for a variety of ailments.12 The major chemical 
constituents of the plant are reported to be carbazole 
alkaloids, coumarins and flavonoids.13 M. koenigii leaf 
extract (MLE) exhibits hypoglycemic and 
hypolipidemic effects in experimental animals.14,15 
Carbazole alkaloids and methanolic extracts of M. 
koenigii are reported to possess anti-oxidative16,17, anti-
diarrheal and anticancer properties.18,19 Recently we 
reported that the aqueous-methanolic extract of 
Murraya koenigii inhibits proteasomal activity in breast 
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cancer cell lines and that this inhibition was associated 
with tumor cell apoptosis.20 Further, the extract 
inhibited proteasomal activity only in cancer cells but 
not in normal cells.20 In recent years there has been a 
rise in breast, prostate, liver and colon cancers in the 
developing world including India and this has been 
attributed to genetic and environmental factors, 
adaptation of western lifestyle and unhealthy eating 
habits.21 Hence, in the present study we examined the 
effect of the MLE on cell viability and proteasomal 
activity in a panel of four human carcinoma cell lines 
namely; colon, prostate, liver and cervical carcinoma 
cells. 
  
Materials and Methods 
Cell lines, Chemicals and Reagents  
Caco2 (human colon carcinoma cell line), 
HepG2 (human hepatocellular liver cell line), HeLa 
(human cervical carcinoma cell line) and LNCaP 
(human prostate carcinoma cell line) were obtained 
from the National Centre for Cell Sciences, Pune, 
India. Cell lines were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% 
FBS, 2 mM Higluta-XL, 100 units/mL penicillin, 100 
μg/mL streptomycin and 0.5 ng/mL amphotericin B, 
1mM sodium pyruvate and 1 × non-essential amino 
acid mixture. All cell lines were grown at 37˚C in a 
humidified atmosphere of 5% CO2. 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide 
(MTT), dimethylsulfoxide (DMSO), dithiothreitol 
(DTT) and crystal-violet, were purchased from Sigma-
Aldrich (St Louis, MO,USA). The fluorogenic 
proteasomal peptide substrate: Suc-LLVY-AMC, and 
MG-132 (carbobenzoxy-Leu-Leu-leucinal; a specific 
inhibitor of the 26S proteasome was procured from 
ENZO Life sciences, USA. All other reagents were 
procured from Qualigens fine chemicals (Mumbai, 
India). DMEM, antibiotic antimycotic mix, sodium 
pyruvate and non-essential amino acid mix were 
purchased from Himedia (Mumbai, India); fetal bovine 
serum (FBS) was purchased from (GIBCO, Invitrogen 
USA). 
 
Plant material  
Murraya koenigii leaves were collected from the 
local area from a single tree. Identity of the leaves was 
confirmed by Dr. B. Pratibha Devi, Professor and 
Head, Department of Botany, Osmania University, 
Hyderabad, India. A voucher specimen (voucher no: 
068) was deposited in a herbarium at the Department 
of Botany, Osmania University, Hyderabad, India. 
 
 
Extraction of leaves  
M. koenigii leaves were washed and air dried in 
shade for 3 weeks. After drying, the leaves were 
ground to a fine powder using an electric mixer 
grinder. The leaf powder was extracted with 80% 
methanol in water by keeping on a vortex mixer for 3-
4 days. This was followed by centrifugation of the 
extract at 5000 rpm for 30 min. The supernatant was 
filtered using a 0.4 μM filter (Millipore). The resultant 
aqueous-methanolic extract was stored in aliquots at -
20°C and was used for all our studies. The leaf extract 
designated as ‘MLE’, was used for all the experiments 
at different doses based on their total phenolic content 
[equivalent to µg of GAE/mL] measured 
spectrophotometrically by the Folin-Ciocalteau 
method. 
 
Cell viability/proliferation assay  
The cytotoxic effects of MLE in cancer cell 
lines were determined by a rapid colorimetric assay, 
using 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT). This assay is based on the 
metabolic reduction of soluble MTT by mitochondrial 
enzyme activity of viable cells into an insoluble 
colored formazan product, which can be measured 
spectrophotometrically at 595 nM after dissolution in 
DMSO. Briefly, cells were plated in 96-well plates at a 
density of 50, 000 cells/well. Different concentrations 
of MLE varying from 1.5–37.5 µg GAE/mL were 
added and cells incubated for 24h at 37°C. MTT was 
added to a final concentration of 100µg/well and 
incubated for further 3h at 37°C. The formazan 
crystals formed were solubilized in DMSO and 
incubated for 1h at room temperature and the 
absorbance was measured at 595 nm in an ELISA 
plate reader (Biotek, New York, USA). All samples 
were assayed in triplicate in three independent 
experiments, and the mean value was calculated. The 
results are expressed as the mean ± SEM and are 
expressed as percentage of control which was 
considered to be 100%.  
 
Colony formation assay  
Cells were plated in triplicate at a density of 
104 cells/well in 12-well plates. The cells were treated 
with concentrations of MLE ranging from 1-75 µg 
GAE/mL and incubated at 37°C and 5% CO2 for one 
week. After a week, the cells were fixed with 4% 
paraformaldehyde for 15 min followed by staining 
with 0.005% crystal violet. The cells were 
photographed with a digital Nikon D90 camera. Three 
independent experiments were done with each cell 
line. 
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Inhibition of proteasome activity in intact tumor cells 
In order to measure the inhibition of the 
proteasome activity in living tumor cells, cells were 
plated at a density of 1×104 in a 24-well plate. Next 
day, cells were treated with concentrations of MLE 
ranging from 3-70 µg GAE/mL. After 24h of 
treatment, the media was aspirated out and 500μl of 1 
× PBS added, to which was added fluorogenic 
substrate (20 μM final concentration) specific for the 
chymotrypsin-like (Ch-L) activity of the 26S 
proteasome. After 2h incubation at 37°C, 200 μL was 
transferred into a black plate and the free 7-amino-4-
methylcoumarin (AMC) liberated was measured 
fluorimetrically in a multi-mode reader [Spectra Max 
M5] at excitation (380 nm) and emission (460 nm). 
The results are shown as mean ± SEM and are 
expressed as a percentage of the control, which was 
considered to be 100%. All samples were assayed in 
triplicate in three independent experiments. 
 
Inhibition of proteasome activity in cell extracts  
Cells (1×107) were harvested, washed twice in 
1 × PBS and re-suspended in 1 mL ATP/DTT lysis 
buffer [10 mM Tris-HCL (pH 7.8), 5 mM ATP, 0.5 
mM DTT, 5 mM MgCl2]. Cells were incubated on ice 
for 10 min, followed by sonication for 15 seconds. 
The lysate was centrifuged at 2000 rpm for 10 min at 
4°C. The supernatant enriched in proteasomes was 
mixed with glycerol (20% final concentration), 
aliquoted and stored at -80°C, and was stable for at 
least 1 month. The total protein content of the cell 
extract was estimated by the bicinchoninic acid (BCA) 
method using a kit (Bangalore Genei, Bangalore, 
India). The assay was carried out in a total of 200μl 
reaction volume containing cell extract (50 μg protein), 
50 mM EDTA, concentrations of the MLE ranging 
from 15-500µg GAE/mL were used for Caco2, 
HepG2 and LNCaP cell lines, whereas the 
concentration of MLE used for HeLa ranged between 
50µg-2mg GAE/mL. MG-132 was used at 
concentrations of 2-400 nM for the different cell lines 
tested. 50 μM of the fluorogenic substrate specific for 
Ch-L activity of the 26S proteasome was added and 
incubated for 2h at 37°C. The amount of free 7-
amino-4-methylcoumarin (AMC) liberated was 
measured fluorimetrically. The results are expressed as 
mean ± SEM as a percentage of the control, which 
was considered to be 100%. All samples were assayed 
in triplicate in three independent experiments. 
 
Statistics 
All experiments were performed in triplicates and 
repeated at least three times and the data is 
represented as mean± SEM. Mean values were 
compared across concentrations of MLE/MG-132 
using non-parametric test of Kruskal-Wallis One-way 
ANOVA for each cell line using the SPSS statistical 
software. Differences between vehicle and MLE/MG-
132 treatments for a particular cell line were 
considered significant at α (probability) level of P </= 
0.05. 
 
Results  
M. koenigii leaf extract decreases cell viability of cancer cells  
The Total Phenolic Content (TPC) of the 
aqueous-methanolic extract of M. koenigii leaves was 
found to be 5μg of gallic acid equivalents (GAE)/μL 
of the MLE. MTT assays were performed with 
different concentrations of MLE (GAE/ml) in four 
human tumor cell lines at 24h time point to assess the 
effect of the extract on cell viability. A time and dose-
dependent decrease in cell viability was observed in all 
the cell lines tested. There was a significant (P < 0.05) 
decrease in cell viability at all doses tested compared to 
vehicle treated cells in HeLa and Caco2 cell lines. On 
the other hand in HepG2 and LNCaP cells, decrease 
in viability was significant (P < 0.05) from 15 µg/ml 
and 12 µg/mL respectively.  The 50% Inhibitory 
concentration (IC50) was found to be 8.07 µg/mL for 
Caco2 cell line, 4.8 µg/mL for HeLa cell line, 17.55 
µg/mL for HepG2 cell line and 16.45 µg/mL for 
LNCaP cell line respectively (Fig 1A-D).  
 
M. koenigii leaf extract alters growth kinetics of cancer cells  
To test the effect of MLE on growth kinetics 
colony formation assay was used, wherein cells were 
seeded at a lower density and treated with varying 
concentrations of the MLE. Colonies were 
photographed after a week. Similar to MTT assay 
there was a dose-dependent decrease in the number of 
colonies in the different cell lines. No colonies were 
seen at MLE concentrations of 6 µg/mL for Caco2, 
18 µg/mL for HeLa, 9 µg/mL for HepG2 and 7.5 
µg/mL for LNCaP respectively (Fig 2A-D). 
 
M. koenigii leaf extract inhibits cellular 26S proteasome activity 
in intact cells  
Whether the MLE inhibits activity of the 26S 
proteasome in living cancer cells, was assessed in the 
four cancer cell lines.  There was a dose dependent 
and significant (P<0.05) decrease in the chymotrypsin-
like activity of the 26S proteasome in intact LNCaP 
and HepG2 cells. On the other hand in Caco2 and 
HeLa cells the decrease in Ch-L activity was 
significantly (P<0.05) different from 6 µg/mL 
compared to vehicle control. The IC50 values were 
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12.5 µg/mL for Caco-2, 7.99µg/mL for HeLa cells 
43.4µg/mL for HepG2 cells and 12.4 µg/mL for 
LNCaP cells respectively (Fig 3A-D). 
 
 
 
 
 
 
 
 
 
Figure1. Murraya leaf extract decreases cell viability of human cancer 
cells: Panels A-D shows results of MTT assay after 24h treatment with MLE 
in Caco2, HeLa, HepG2 and LNCaP cells respectively. The data 
represents mean+/-SEM of three independent experiments. 'V' in the 
figure stands for vehicle treated cells. 
 
 
 
Figure 2. Murraya leaf extract alters growth kinetics of human cancer 
cells: Panel A-D depicts results of colony formation assay in Caco2, HeLa, 
HepG2 and LNCaP cells respectively. Cells were grown in 6-well plates 
and treated with various concentrations of the MLE. After a week cells 
were stained with crystal violet and photographed. 
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Figure3. Inhibition of the enzymatic activities of the 26S proteasome by 
the MLE in intact cancer cells: Intact cells were treated for 24h 
with/without the MLE followed by 2h incubations at 37C with a 
fluorogenic substrate for Ch-L activity. The fluorescent intensity of the 
free AMCs was determined in a multimode reader with excitation at 380 
nm and emission at 460 nm. Each activity was expressed as percentage 
of control (defined as 100%). Panels A-D shows results from Caco2, 
HeLa, HepG2 and LNCaP cells respectively. The data represents mean 
+/- SEM of three independent experiments. V in the figure stands for 
vehicle treated cells. 
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Figure 4. Inhibition of the enzymatic activities of the 26S proteasome by 
the MLE in human cancer cell extracts: Cell extracts (=50 µg protein) 
were incubated with 50 µM of the fluorogenic substrate for Ch-L like 
activity in the presence of various concentrations of the MLE for 2h at 
37C. The fluorescent intensity of the free AMCs was determined at 380 
nm (exc) 460 nm (emi).Each activity was expressed as percentage of 
control (defined as 100%). Panels A-D shows results from Caco2, HeLa, 
HepG2 and LNCaP cells respectively. The data represents meanSEM of 
three independent experiments. V in the figure stands for vehicle treated 
cells. 
 
M. koenigii leaf extract inhibits cellular 26S proteasome activity 
in cell extracts 
In order to confirm that the MLE does inhibit 
the 26S proteasome, cell extracts enriched in 26S 
proteasomes were prepared from all the tumor cell 
lines. MLE inhibited the Ch-L like activity of 26S 
proteasome in a dose-dependent manner. There was a 
significant decrease (P<0.05) in Ch-L like activity in 
HeLa and Caco2 cells from 100 µg/mL, whereas in 
HepG2 and LNCaP it was 15 µg/mL and 50 µg/mL 
respectively. The IC50 values were 216 µg/mL in 
Caco2, 349.7 µg/mL in HeLa, 51.9 µg/mL in HepG2 
cells and 344.7 µg/mL in LNCaP cells respectively 
(Fig 4A-D). 
As a positive control MG-132, a specific, 
reversible proteasome inhibitor was also tested. It was 
observed that MG-132 significantly (P<0.05) 
decreased, the chymotrypsin-like activity of the 26S 
proteasome in a dose-dependent manner in cell 
extracts prepared from all cell lines with an IC50 of 
132.8 nM in Caco2 cells, 78.6 nM in HeLa, 14.23 nM 
in HepG2 cells and 70.9 nM in LNCaP cells 
respectively (Fig 5A-D). 
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Figure 5. Inhibition of the enzymatic activities of the 26S proteasome by 
the proteasome specific inhibitor, MG-132 in human cancer cell extracts: 
Cell extracts (= 50 µg protein) were incubated with 50 µM of the 
fluorogenic substrate specific for Ch-L like activity in the presence of 
various concentrations of MG-132 for 2h at 37C. Each activity was 
expressed as percentage of control (defined as 100%). Panels A-D 
shows results from Caco2, HeLa, HepG2 and LNCaP cells respectively. 
The data represents meanSEM of three independent experiments. V in 
the figure stands for vehicle treated cells. 
                             
Discussion  
Cancer is a disease where the treatment can be 
as debilitating as the disease itself. Drug resistance 
limits the effectiveness of existing treatment options 
and is a major challenge faced in current cancer 
research.  Use of complementary and alternate forms 
of medicine for the treatment of cancer is now being 
explored of which herbal medicine is preferred due to 
minimal or no side effects.22. Studies have shown that 
a diet high in fruits and vegetables is associated with a 
reduced risk of cancer.23. A recent approach in cancer 
therapy is the inhibition of the proteolytic machine – 
the 26S proteasome.5 Unlike normal cells, cancer cells 
are known to have very high proteasome activity, 
which is needed for their survival and uninhibited 
proliferation3, and inhibition of the proteasome leads 
to apoptosis and cell death.  Importantly, proteasome 
inhibitors have been demonstrated to induce cell death 
only in tumor cells but not in normal cells.5,7 
Bortezomib/Velcade/PS-341 is the first-in-line 
proteasome inhibitor to be approved by the FDA in 
2003 for the treatment of multiple myeloma.24 
Subsequently, bortezomib was tested in a variety of 
hematological and solid tumors including non-
Hodgkin’s lymphoma, prostate, breast and non-small 
cell lung cancer. Nevertheless, synthetic proteasome 
inhibitors are associated with some toxicity. Dietary 
polyphenols such as apigenin, quercetin, 
epigallocatechin gallate (EGCG) have been reported 
to act as proteasome inhibitors and anticancer 
agents.25 Therefore, proteasome inhibitors from 
natural food sources with minimal or no toxicity can 
be potential anticancer agents. M. koenigii leaves are a 
rich source of polyphenols/flavonoids.26 Studies on 
the anticancer potential of M. koenigii leaves are scarce. 
Mahanine, a carbazole alkaloid isolated from 
M.koenigii leaves is reported to inhibit cell growth and 
induce apoptosis in prostate and leukemia cancer 
cells.19 Recently we reported the cytotoxic and 
proteasome inhibitory effect of M. koenigii leaf extract 
in breast cancer cells.20 Interestingly, we observed that 
M. koenigii leaf extract could inhibit the proteasome 
activity only in cancer cells but not in normal cells.20 
Therefore, we tested the efficacy of M. koenigii leaf 
extract in inhibiting the proteasomal activity of human 
colon, cervical, liver and prostate carcinoma cell lines. 
We observed that the MLE dose-dependently 
decreased the viability in all the cell lines tested, 
although a differential response was observed in the 
different cell lines. This was further corroborated by 
the significant reduction in the number of colonies in 
MLE treated cells compared to vehicle treated cells. 
Our cell viability and colony formation results show 
that MLE altered the growth kinetics of all the tumor 
cell lines tested. We next tested the potential of the 
MLE in inhibiting the chymotrypsin-like proteolytic 
activity of the proteasome in the different tumor cell 
lines. MLE inhibited the Ch-L activity of the 
endogenous 26S proteasome in both living cells and 
cell extracts. The major constituents in M. koenigii 
leaves are known to be alkaloids, flavonoids and 
coumarins.13 A few isolated alkaloids have been 
demonstrated to arrest growth of cancer cells by 
mechanism(s) other than proteasome inhibition.16 On 
the other hand, dietary flavonoids are reported as 
proteasome inhibitors and anticancer agents.7 
Therefore, it is probable that the proteasome 
inhibitory activity of MLE is by virtue of its high 
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flavonoid content. Our results suggest that MLE could 
induce cell death and inhibit the cellular proteasome in 
the different cancer cell lines. In summary, our data 
indicates that M. koenigii leaves can inhibit cell 
proliferation and proteasome activity in four different 
human cancer cell lines. Proteasome inhibition is 
probably one mechanism that causes cell death upon 
treatment with MLE. Therefore, isolation and 
characterization of active component(s) from M. 
koenigii leaves that possess proteasome inhibitory 
potential could lead to the development of novel 
anticancer drugs. 
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